Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy

Kafrelsheikh University

Status: Completed

Conditions: Mastectomy; Erector Spinae Plane Block; Bupivacaine; Dexmedetomidine; Pain Management; Serratus Anterior Plane Block; Ultrasound

Treatments: Drug: Bupivacaine + Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT06737458

KFSIRB200-438

Details and patient eligibility

About

This study aimed to compare the serratus plane block versus the erector spinae plane block with dexmedetomidine added to bupivacaine for acute pain management after breast surgeries.

Full description

Approximately 40-60% of breast surgery patients endure severe acute postoperative pain, with over 10% of patients experiencing severe pain for six to twelve months (post-mastectomy pain syndrome).

Dexmedetomidine has analgesic properties, which could be related to the stimulation of α2 adrenoceptors, inhibition of nerve conduction through C and Aδ fibers, and the local release of encephalin.

Serratus plane block (SPB) is an effective approach for breast surgery analgesia due to its simplicity of delivery, minimal risk of adverse effects, and ability to provide significant pain relief.

The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB can be given unilaterally during modified radical mastectomy.

Enrollment: 40 patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women aged >20 years.
• Patient's approval.
• American Society of Anesthesiologists (ASA) physical status I-II.
• Patients underwent breast surgeries.

Exclusion criteria

• Known allergy to local anesthetics, opioids, or dexmedetomidine medications.
• Advanced heart block, ventricular dysfunction.
• Skin infection at the site of injection.
• Pre-existing chronic pain.
• Coagulopathies, significant liver or renal insufficiency.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Serratus anterior plane block group

Active Comparator group

Description:

Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.

Treatment:

Drug: Bupivacaine + Dexmedetomidine

Drug: Bupivacaine + Dexmedetomidine

Erector spinae plane block group

Experimental group

Description:

Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.

Treatment:

Drug: Bupivacaine + Dexmedetomidine

Drug: Bupivacaine + Dexmedetomidine